Background: Troponin testing in acute medicine is routine. The introduction of a high sensitivity assay (hs Tn T) has created uncertainty regarding the clinical significance of 'abnormal' troponin T levels. The previous assay could not detect troponin levels <30 ng/l. Aims and methods: To characterize those with a hs Tn T 514 ng/l. Prospective cohort study of consecutive admissions to an acute medical unit. Results: Troponin was measured in 564 consecutive patients ($50% of all admissions) over 1 month; was 514 ng/l in 224 (40%) of which 220 patients had demographic data for this analysis. Median (inter-quartile range) peak troponin was 47.5 ng/l (24-130) and 36% had a Tn T between 14 and 30 ng/l. Mean [standard deviation (SD)] age was
Summary
Background: Troponin testing in acute medicine is routine. The introduction of a high sensitivity assay (hs Tn T) has created uncertainty regarding the clinical significance of 'abnormal' troponin T levels. The previous assay could not detect troponin levels <30 ng/l. Aims and methods: To characterize those with a hs Tn T 514 ng/l. Prospective cohort study of consecutive admissions to an acute medical unit. Results: Troponin was measured in 564 consecutive patients ($50% of all admissions) over 1 month; was 514 ng/l in 224 (40%) of which 220 patients had demographic data for this analysis. Median (inter-quartile range) peak troponin was 47.5 ng/l (24-130) and 36% had a Tn T between 14 and 30 ng/l. Mean [standard deviation (SD)] age was 72 (12) years and 57% were male. Only 44 patients (20%) had an acute myocardial infarction, reflecting the increased sensitivity but reduced specificity of the assay. Prognosis was poor with 31% mortality at 1 year. Over a mean (SD) follow-up of 648 (61) days, there were 87 deaths (40%). Those with a primary non-cardiac diagnosis (n = 126) had poorer survival than those with a primary cardiac diagnosis (n = 94). Troponin elevation related to sepsis conferred a very poor prognosis with 24 deaths (70%) over the follow-up period. Conclusions: Elevated hs Tn T is very common in acute medicine, but myocardial infarction as an explanation is uncommon. Overall, the prognosis is poor with a tendency to worse outcomes in those with a primary 'non-cardiac' diagnosis.
Background
Detection of circulating cardiac troponin indicates and provides an estimate of cardiomyocyte damage irrespective of its cause. The new fifth generation high sensitivity assays can detect circulating troponin T in normal individuals. Rising and/or falling levels of troponin should differentiate acute from chronic cardiomyocyte damage. The differential diagnosis of very high levels of troponin is mainly acute myocardial infarction (AMI), myocarditis and takotsubo cardiomyopathy. There are many causes of minor elevations in troponin, including acute and chronic cardiac disorders and these may or may not be associated with short-term changes in troponin levels.
1-3 A troponin T cut off <14 ng/l represents the 99th centile for healthy subjects. 4, 5 Detecting troponin in the circulation confers prognostic importance in healthy 6 and asymptomatic patients with stable vascular disease, 4 acute coronary syndromes [7] [8] [9] [10] and heart failure [11] [12] [13] [14] [15] in the intensive care setting 16, 17 and in hospitalized patients. 18 Troponin testing is commonplace in acute medical units (AMU). However, the prevalence, characterization and prognostic significance of troponin elevation with the newer high sensitivity assay in such a setting is not well defined.
Aims and methods
To characterize a patient cohort, who attended an AMU and were found to have a high sensitivity troponin T 514 ng/l. We prospectively looked at consecutive patients attending an AMU in a busy district general hospital, over a 1 month period, who had a high sensitivity troponin T checked (for whatever reason). For any patient that attended more than once, only the first hospital attendance was taken into account. When multiple troponin samples were taken from a patient, the peak level was recorded. Troponin T was measured by Roche diagnostics, as part of routine hospital care. 
Results
In total, 564 consecutive patients ($50% of all admissions) had troponin measured; in 224 (40%) it was 514 ng/l. Case notes were missing in four patients, thus the study cohort consisted of 220 patients with demographic information available. Data regarding interval change in troponin levels are from the 178 patients who had a repeat sample taken within 6-12 h. Overall, the mean (SD) age of the study population was 72 (12) years (range: 30-95 years); 57% of the study population was male with a mean (SD) male age of 69 (11) years and mean (SD) female age of 75 (12) years. The baseline demographics of the study population when stratified according to diagnosis of acute myocardial infarction or not is shown in Table 1 . Only 44 (20%) of patients had a final diagnosis of acute myocardial infarction, as per the universal definition. 9 They were younger, had higher peak troponin levels, lower C-reactive protein levels and were more likely to present with chest pain, have ST segment deviation on an ECG and undergo in-patient coronary angiography. Table 2 shows the principal diagnoses with corresponding peak troponin level and relative changes in troponin T. Those with a relative change of <20% (rise or fall) were more likely to have an underlying diagnosis of heart failure, sepsis, renal dysfunction or lung disease. Those classified as 'not significant' were patients where we found no significant diagnosis and tended to be older. Those classified as 'other' included a diverse range of problems as illustrated in the key at the foot of Table 2 . Table 3 illustrates the principal ECG findings, along with corresponding peak troponin level. ST segment elevation was associated with the highest troponin values, followed by ST segment depression. One was more likely to undergo in-patient coronary angiography if there was ST segment deviation (elevation or depression) or T-wave inversion on the ECG (P = 0.033). Normal sinus rhythm and atrial fibrillation were common findings. Table 4 shows baseline characteristics according to the history of presenting complaint. Chest pain was common, seen in 38%, followed by breathlessness in 27%. Other modes of presentation to hospital included collapse, pre-syncope and palpitations. Often presentation was non-specific and the clinical indication for measuring serum troponin was unclear. Only chest pain presenters went on to have in-patient coronary revascularization and were more likely to have a relative increase in serum troponin of >100%. Four patients went on to have coronary artery by-pass grafting and one patient died as an inpatient before this was undertaken. There were weak but statistically significant correlations between troponin and haemoglobin (r = À0.222; P < 0.01), troponin and creatinine (r = 0.173; P < 0.05) and troponin and C-reactive protein (r = 0.238; P < 0.01). There was no correlation between troponin and age or troponin and white cell count.
We found one-third of patients had a >20% rise and one-fifth had a >100% rise in subsequent 
Survival
Over a mean (SD) follow-up of 648 (61) days there were 87 deaths (40%). Mortality at 30 days following admission was 12.5% and at 1 year was 31%. Figure 1 illustrates a Kaplan-Meier survival curve according to those with a primary cardiac diagnosis (n = 94) vs. the rest (n = 126) of the study population.
Those with a non-cardiac diagnosis vs. a primary cardiac diagnosis, were of similar age with a mean (SD) of 72. Values are numbers of patients (percentages). Bold is used to highlight P-values that are significant i.e < 0.05.
Continuous data expressed as mean (SD) or median (IQR).
Áhs Tn T, change in high sensitivity troponin T; Hb, haemoglobin; WCC, white cell count; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; LVSD, left ventricular systolic dysfunction. fashion. Figure 2 illustrates a Kaplan-Meier survival curve according to those with a primary diagnosis of 'sepsis' vs. the rest of the study population. Survival was very poor in this cohort, with continued events after hospital discharge. Nearly half (47.8%) of those with ST segment depression on an ECG died during follow-up, compared with 22% for those with ST segment elevation. We found no difference in survival according to whether one had a rise or fall in subsequent troponin T, regardless of the magnitude. Interestingly in those whose troponin remained within 20% on repeat testing had worse outcomes than those whose troponin changed acutely, perhaps a manifestation of systemic illness rather than 'acute' myocardial ischaemia per se. Troponin level across tertiles predicted survival, but this was not an independent predictor in a multivariate analysis. Those classified as 'non-significant' (only because the clinicians involved deemed the troponin result to be as such and no other 'classifying' diagnosis was evident), still had six deaths over the followup period (on Days 2, 41, 119, 125, 133 and 528). Figure 3 illustrates a Kaplan-Meier survival curve according to those who underwent in-patient coronary angiography (irrespective of revascularization) vs. those who were managed conservatively. In-patient coronary angiography and subsequent revascularization were univariate predictors of survival but not independent predictors. In a multivariate Cox-regression survival analysis, independent predictors of survival were elevated C-reactive protein (CRP); hazard ratio (HR) 1.005; confidence interval (CI) 1.003-1.007; P < 0.001, increasing age (HR 1.033; CI 1.002-1.065; P = 0.040) and non-treatment with enoxaparin (HR 4.54; CI 1.22-16.9; P = 0.024).
Discussion
A previous study looking at troponin I in hospitalized patients reported a diagnosis of acute coronary syndrome in 65% and also found that 'non-acute coronary syndrome' troponin elevations were associated with worse clinical outcomes. 20 Iversen et al. 18 recently reported on a historic cohort of patients attending a district hospital over a 1-year period and also found a high frequency of elevations in high sensitivity troponin T. However, this is, to the best of our knowledge, the first study to characterize contemporary patients attending an acute medical unit using the new fifth generation high sensitivity troponin T assay. The low frequency of myocardial infarction is likely to reflect the increased sensitivity but reduced specificity of this assay. Patients with chronic heart failure and minor troponin elevation have a worse prognosis than those with infrequent but significant rises in troponin. 12, 21 We found a similar trend to worse outcomes in our cohort in those whose troponin did not change by more than a factor of 20%, (and this was significant in a univariate survival analysis) but our study population was too small to make any firm conclusions. Among patients treated for sepsis in intensive care, elevated troponin levels have been detected with a median frequency of 43% according to a recent meta-analysis. 16 The mechanism of troponin release is not clear but theories include oxygen supplydemand mismatch related to hypotension, hypoxaemia and micro-circulatory dysfunction as well as direct toxic effects on cardiac tissue from endotoxins, cytokines and free radicals. 17, 22, 23 Elevation of troponin in stable and infective exacerbations of COPD is associated with adverse outcomes. [24] [25] [26] In a recent study of 1181 patients presenting with chest pain, only 15% had a high sensitivity troponin T > 14 ng/l and in this study, age was the strongest predictor of elevated troponin. 27 In contrast, we found absolutely no correlation between age and troponin. Chronic kidney disease is associated with elevated troponin T and high sensitivity troponin T is reported to be 514 ng/l in virtually all patients on dialysis. [28] [29] [30] Rather curiously, three patients had no ECG performed. Although clearly not an acceptable 'standard of care' it does illustrate the rather indiscriminate use of troponin testing in unscheduled medical admissions. The low rate of coronary angiography in this cohort reflects the percentage of patients thought to have had an acute ischaemic event rather than elevations in troponin related to systemic illness. However, the decision making around who gets invasive testing depends on who is referred to cardiology, and the precise 'setting' of the abnormal troponin levels. Often, a more conservative approach is reserved for patients with multiple co-morbid conditions and degrees of 'frailty' which are difficult entities to quantify objectively. Given the current lack of clinical evidence that supports routine coronary angiography for patients with elevated troponin, clearly out with the setting of acute ischaemia, this strategy is perhaps very reasonable. Our centre has a primary angioplasty service for ST elevation myocardial infarction and unstable acute coronary syndromes, but does not currently have routine access to computed tomography coronary angiography (CTCA) or cardiac magnetic resonance imaging (CMR). None of the patients in this cohort underwent CTCA, which may have added useful information regarding the presence of coronary artery disease and possible mechanisms underlying troponin release. Only one patient underwent CMR (at another centre) and was diagnosed with myocarditis. What is not clear is whether such patients require invasive investigations rather than addressing the underlying cause. Is there a need for further assessment, specifically to look for the presence of coronary artery disease, in the out-patient setting after recovery from any acute illness? Can this adverse outcome be modified by conventional therapies used in acute coronary syndromes including anti-platelet agents, low molecular weight heparin and b-blockers or is a 'common sense' approach of treating the underlying illness all that is required? Indiscriminate use of such agents outwith the setting of 'atherosclerotic plaque rupture and thrombus formation' may increase bleeding risk without any net clinical benefit. The high prevalence of troponin elevations has implications for cardiology services given the clinical uncertainty that has arisen with the new assay. 31 Great care is also required to avoid making an erroneous diagnosis of myocardial infarction based on troponin level only. This has very real downstream ramifications for patients regarding health insurance, ability to obtain travel insurance policies and driving regulations, among others. Different cut off levels of troponin may be needed for men and women, and for diabetics and the elderly, who often manifest a different distribution of cardiac troponin concentrations. [32] [33] [34] As with any diagnostic test, it has to be interpreted in clinical context. Changes in troponin are likely to be more relevant than absolute values and the use of terms such as 'troponin positive' should be discouraged.
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Study limitations
The sample size of the population studied was relatively small and the non-randomized nature of the study has the potential to introduce bias. However, we collected data on consecutive patients to reduce such bias. The patients with sepsis accounted for only 34 and within this cohort there was still a wide variety of final diagnoses. Given this variation in diagnoses it is likely to be a wide range of possible patho-physiological mechanisms involved. We do not have (reliable) demographics regarding the presence of diabetes, hypertension, prior myocardial infarction, ischaemic heart disease or the presence of vascular disease (and thus possibly occult coronary artery disease). Aside from aspirin, clopidogrel and warfarin therapy, we do no not have information regarding baseline or post-hospital discharge medical therapy that may influence survival. We do not have data on the cause of death or data regarding repeat hospitalization with specific regard to cardiovascular reasons.
Conclusions
In an unselected cohort of patients attending an acute medical unit, high sensitivity troponin T levels 514 ng/l was very common. Clinical presentation was varied and the majority (80%) did not have a diagnosis of acute myocardial infarction. Care is required to avoid erroneously diagnosing AMI based on troponin alone. Overall, the prognosis was poor with continued deaths following hospital discharge. Those with primarily 'non-cardiac' diagnoses tended to have poorer outcomes. Further research into this heterogeneous but high-risk patient group is warranted.
